

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): An immunogenic peptide constituting a T epitope presented by MHC I, ~~characterized in that it~~ wherein said immunogenic peptide consists of a fragment of 8 to 11 consecutive amino acids of the EphA2 antigen.

Claim 2 (Currently Amended): The immunogenic peptide as claimed in claim 1, ~~characterized in that it is chosen from~~ wherein the immunogenic peptide is selected from the group consisting of:

- the peptide of sequence IMNDMPIYM (SEQ ID NO: 4);
- the peptide of sequence VLLLVLGV (SEQ ID NO: 6);
- the peptide of sequence VLAGVGFFI (SEQ ID NO: 7); and
- the peptide of sequence TLADFDPRV (SEQ ID NO: 8).

Claim 3 (Currently Amended): An immunogenic peptide constituting a T epitope presented by MHC I, ~~characterized in that it~~ wherein said immunogenic peptide is derived from a peptide consisting of a fragment of 8 to 11 consecutive amino acids of the EphA2 antigen, by substitution of at least one amino acid of said peptide with an amino acid which increases the affinity of said peptide for an MHC I allele.

Claim 4 (Currently Amended): The peptide as claimed in claim 3, ~~characterized in that it~~ wherein said peptide is derived from a peptide consisting of a fragment of 8 to 11 consecutive amino acids of the EphA2 antigen, by substitution of the N-terminal amino acid of said peptide with a tyrosine residue.

Claim 5 (Currently Amended): The peptide as claimed in claim 4, ~~characterized in that it is defined by~~ wherein said peptide has the sequence YMPIYMYSV (SEQ ID NO: 9).

Claim 6 (Currently Amended): A polynucleotide encoding a peptide as claimed in ~~any one of claims 1 to 5~~ claim 1.

Claim 7 (Currently Amended): A composition comprising at least one peptide as claimed in ~~any one of claims 1 to 6 or a polynucleotide as claimed in claim 5~~ claim 1.

Claim 8 (Currently Amended): The composition as claimed in claim 7, ~~characterized in that it~~ wherein said composition is a multiepitope composition also comprising ~~one or more~~ at least one selected from the group consisting of other immunogenic peptide(s) ~~or one or more~~ and polynucleotide(s) encoding said other immunogenic peptide(s).

Claim 9 (Currently Amended): The composition as claimed in claim 7, ~~characterized in that it is~~ wherein said composition comprises a chimeric polypeptide comprising at least one selected from a group consisting of a copy of a ~~an immunogenic peptide as claimed in any one of claims 1 to 5 and/or at least one~~ constituting a T epitope presented by MHC I, wherein said immunogenic peptide consists of a fragment of 8 to 11 consecutive amino acids of the EphA2 antigen and a copy of another immunogenic peptide, ~~or a polynucleotide encoding said chimeric polypeptide.~~

Claim 10 (Currently Amended): ~~The use of~~ An immunotherapeutic method, comprising a step of administering a peptide as claimed in ~~any one of claims 1 to 5~~ claim 1,

~~of a polynucleotide as claimed in claim 6 or of a composition as claimed in any one of claims 7 to 9, for obtaining a medicinal product to a patient in need thereof.~~

Claim 11 (Currently Amended): The ~~use as claimed in~~ method of claim 10, characterized in that said medicinal product is intended for antitumor immunotherapy wherein said patient suffers from cancer.

Claim 12 (Currently Amended): The ~~use as claimed in~~ method of claim 11, characterized in that said medicinal product is intended for the immunotherapy of tumors wherein said patient has a tumor expressing the EphA2 antigen.

Claim 13 (Currently Amended): The ~~use as claimed in any one of claims 10 to 12,~~ characterized in that said medicinal product is intended for the treatment of method of claim 10 wherein said patient is an HLA-A\*0201 patient patients.

Claim 14 (New): A composition comprising at least one polynucleotide as claimed in claim 6.

Claim 15 (New): The composition as claimed in claim 14, wherein said composition is a multiepitope composition also comprising at least one selected from the group consisting of other immunogenic peptides and polynucleotides encoding said other immunogenic peptides.

Claim 16 (New): The composition as claimed in claim 14, wherein said composition comprises a polynucleotide encoding a chimeric polypeptide comprising at least one selected

from the group consisting of a copy of an immunogenic peptide constituting a T epitope presented by MHC I wherein said immunogenic peptide consists of a fragment of 8 to 11 consecutive amino acids of the EphA2 antigen and a copy of another immunogenic peptide.

Claim 17 (New): The composition as claimed in claim 14 wherein said composition comprises a chimeric polypeptide comprising at least one selected from a group consisting of a copy of an immunogenic peptide constituting a T epitope presented by MHC I wherein said immunogenic peptide consists of a fragment of 8 to 11 consecutive amino acids of the EphA2 antigen, a copy of another immunogenic peptide and a polynucleotide encoding said chimeric polypeptide.

Claim 18 (New): An immunotherapeutic method, comprising a step of administering a polynucleotide as claimed in claim 6, to a patient in need thereof.

Claim 19 (New): The method of claim 18 wherein said patient suffers from cancer.

Claim 20 (New): The method of claim 19 wherein said patient has a tumor expressing the EphA2 antigen.

Claim 21 (New): The method of claim 18 wherein said patient is an HLA-A\*0201 patient.

Claim 22 (New): An immunotherapeutic method, comprising a step of administering the composition as claimed in claim 7, to a patient in need thereof.

Claim 23 (New): The method of claim 22 wherein said patient suffers from cancer.

Claim 24 (New): The method of claim 23 wherein said patient has a tumor expressing the EphA2 antigen.

Claim 25 (New): The method of claim 22 wherein said patient is an HLA-A\*0201 patient.

Claim 26 (New): An immunotherapeutic method, comprising a step of administering the composition as claimed in claim 14, to a patient in need thereof.

Claim 27 (New): The method of claim 26 wherein said patient suffers from cancer.

Claim 28 (New): The method of claim 27 wherein said patient has a tumor expressing the EphA2 antigen.

Claim 29 (New): The method of claim 26 wherein said patient is an HLA-A\*0201 patient.